Innovent Biologics, Inc.
IVBXFOTCHealthcare● Active
$9.10
$-0.99(-9.85%)
Market Cap$15.8B
P/E Ratio—
52W High$15.12
52W Low$9.01
Innovent Biologics, Inc. (IVBXF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IVBXF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 26, 2026EPS Actual
-$0.00
Est. $0.02 · -108.3%
Revenue
$1.01B
Est. $0.99B · +2.8%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 26, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
IVBXF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | $0.16 | — | — | — | $1.39B | — |
| ▼ Q1 FY2026 | Mar 26, 2026 | $0.02 | -$0.00 | -108.3% | $1.01B | $0.99B | +2.8% |
| ▲ Q3 FY2025 | Aug 27, 2025 | $0.03 | $0.07 | +173.3% | $0.83B | $0.79B | +5.0% |
| ▲ Q1 FY2025 | Mar 26, 2025 | -$0.03 | $0.03 | +179.4% | $0.75B | $0.64B | +17.6% |
| ▲ Q3 FY2024 | Aug 28, 2024 | -$0.03 | -$0.03 | +3.2% | $0.54B | $0.52B | +4.4% |
| ▼ Q1 FY2024 | Mar 20, 2024 | -$0.07 | -$0.08 | -12.5% | $0.49B | $0.48B | +2.8% |
| ▲ Q2 FY2023 | Jun 30, 2023 | -$0.10 | -$0.01 | +87.4% | $0.37B | $0.36B | +3.7% |
| ▲ Q4 FY2022 | Dec 31, 2022 | -$0.17 | -$0.12 | +30.7% | $0.34B | $0.32B | +7.1% |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
$0.16
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.00
EPS Est.
$0.02
EPS Surpr.
-108.3%
Revenue
$1.01B
Q3 FY2025
Aug 27, 2025Beat
EPS Actual
$0.07
EPS Est.
$0.03
EPS Surpr.
+173.3%
Revenue
$0.83B
Q1 FY2025
Mar 26, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.03
EPS Surpr.
+179.4%
Revenue
$0.75B
Q3 FY2024
Aug 28, 2024Beat
EPS Actual
-$0.03
EPS Est.
-$0.03
EPS Surpr.
+3.2%
Revenue
$0.54B
Q1 FY2024
Mar 20, 2024Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-12.5%
Revenue
$0.49B
Q2 FY2023
Jun 30, 2023Beat
EPS Actual
-$0.01
EPS Est.
-$0.10
EPS Surpr.
+87.4%
Revenue
$0.37B
Q4 FY2022
Dec 31, 2022Beat
EPS Actual
-$0.12
EPS Est.
-$0.17
EPS Surpr.
+30.7%
Revenue
$0.34B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.04 | $0.04 | $0.04 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.18 | $0.18 | $0.18 | 1 |
| Q2 FY2024 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q4 FY2023 | $-0.69 | $-0.69 | $-0.69 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $46.2B | $46.2B | $46.2B | 1 |
| Q3 FY2025 | $6.3B | $6.3B | $6.3B | 1 |
| Q2 FY2025 | $40.6B | $40.6B | $40.6B | 1 |
| Q2 FY2024 | $14.5B | $14.5B | $14.5B | 1 |
| Q4 FY2023 | $24.7B | $24.7B | $24.7B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 26, 2026 | -108.3% | $9.75 | $10.62 | +8.92% |
| ▲ Q3 FY2025 | Aug 27, 2025 | +173.3% | $13.00 | $12.00 | -7.69% |
| ▲ Q1 FY2025 | Mar 26, 2025 | +179.4% | $5.33 | $5.20 | -2.44% |
| ▲ Q3 FY2024 | Aug 28, 2024 | +3.2% | $5.50 | $5.50 | +0.00% |
| ▼ Q1 FY2024 | Mar 20, 2024 | -12.5% | $5.00 | $4.76 | -4.80% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +87.4% | $3.99 | $3.99 | +0.00% |
| ▲ Q4 FY2022 | Dec 31, 2022 | +30.7% | $4.29 | $4.29 | +0.00% |
| ▲ Q2 FY2022 | Jun 30, 2022 | +36.4% | $4.05 | $4.05 | +0.00% |
Q1 FY2026+8.92%
Report Date
Mar 26, 2026
EPS Beat/Miss
-108.3%
Price Before
$9.75
Price After
$10.62
Q3 FY2025-7.69%
Report Date
Aug 27, 2025
EPS Beat/Miss
+173.3%
Price Before
$13.00
Price After
$12.00
Q1 FY2025-2.44%
Report Date
Mar 26, 2025
EPS Beat/Miss
+179.4%
Price Before
$5.33
Price After
$5.20
Q3 FY2024+0.00%
Report Date
Aug 28, 2024
EPS Beat/Miss
+3.2%
Price Before
$5.50
Price After
$5.50
Q1 FY2024-4.80%
Report Date
Mar 20, 2024
EPS Beat/Miss
-12.5%
Price Before
$5.00
Price After
$4.76
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
+87.4%
Price Before
$3.99
Price After
$3.99
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
+30.7%
Price Before
$4.29
Price After
$4.29
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
+36.4%
Price Before
$4.05
Price After
$4.05
Avg Beat Reaction-1.69%
Avg Miss Reaction+2.06%
Beat Rate6 / 8 quarters
Largest Move+8.92% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IVBXF ends December
Innovent Biologics, Inc. (IVBXF) most recently reported earnings on March 26, 2026 for Q1 FY2026, posting EPS of $-0.00 — missing the analyst consensus of $0.02 by -108.3%. The next IVBXF earnings date is expected around September 1, 2026.
Each quarter, investors track IVBXF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IVBXF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IVBXF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IVBXF earnings · 5 questionsInnovent Biologics, Inc.'s next earnings report is expected around September 1, 2026. IVBXF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IVBXF historically reports after market close (AMC).
IVBXF earnings datewhen is IVBXF earningsIVBXF next earnings datewhen does IVBXF report earningsIVBXF earnings calendar
▸ Source: FMP · Innovent Biologics, Inc. SEC filings · US GAAP · Innovent Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026